What is DHT and how does it cause hair loss?
Dihydrotestosterone (DHT) is a male sex hormone and a primary cause of androgenetic alopecia (AGA). The enzyme 5-alpha reductase converts testosterone into DHT. In genetically predisposed individuals, DHT binds to receptors in the scalp, shrinking hair follicles and shortening their growth phase, leading to thinner hair and eventual loss.
The mechanism behind melatonin's effect on hair follicles
Melatonin's impact on hair follicles is complex and appears more indirect than direct DHT blockers like finasteride. Hair follicles have melatonin receptors, suggesting melatonin can directly affect the hair growth cycle. Its proposed mechanisms include:
- Antioxidant and anti-inflammatory properties: Melatonin protects follicles from damage caused by oxidative stress.
- Regulation of the hair cycle: It may extend the anagen (growth) phase of hair, which is shortened in AGA.
- Indirect anti-androgen effects: Research, including animal and in vitro studies, suggests melatonin may interfere with androgens or their receptors, potentially influencing DHT formation, though this is not a direct inhibition of 5-alpha reductase like finasteride.
Comparing Melatonin to Traditional DHT Blockers
The table below highlights how topical melatonin differs from traditional hair loss treatments:
Feature | Melatonin (Topical) | Finasteride (Oral) | Minoxidil (Topical) |
---|---|---|---|
Mechanism | Indirect anti-androgenic effects, antioxidant, prolongs hair growth cycle. | Blocks the 5-alpha reductase enzyme, preventing testosterone from converting to DHT. | Vasodilator that improves blood flow to hair follicles, extending the anagen phase. |
DHT Blocking? | Indirectly influences androgenic pathways, but not a direct 5-alpha reductase inhibitor. | Yes, a direct and powerful DHT blocker. | No, works by a different mechanism. |
Administration | Applied as a topical solution, cream, or serum. | Taken orally as a pill. | Applied topically as a foam or liquid. |
FDA Status | Unregulated dietary supplement for hair loss, not FDA-approved. | FDA-approved treatment for male AGA. | FDA-approved treatment for AGA. |
Side Effects | Mild and temporary, such as scalp irritation, redness, or itching. Oral use can cause drowsiness, dizziness, or headaches. | Potential side effects include sexual dysfunction (e.g., decreased libido), breast tenderness, and mood changes. | Mild side effects like scalp irritation; rare systemic effects. |
Best for | Early-stage AGA, particularly in women, or as an adjunctive therapy. | Moderate to severe AGA in men; requires prescription. | Both men and women with AGA; available over-the-counter. |
Clinical evidence for topical melatonin
Clinical studies on topical melatonin for AGA have shown promising results. A study on women with AGA found that a 0.1% topical melatonin solution increased the anagen hair rate. A large multicenter study with over 1800 participants showed that a cosmetic melatonin solution improved the hair pull test, indicating reduced hair loss, with some reporting new growth. A review of data from over 2,200 patients also indicated improved scalp hair growth and density. These studies emphasize the effectiveness of topical application directly to the scalp for localized action on follicles, contrasting with oral melatonin used primarily for sleep.
The takeaway: Does melatonin function as a DHT blocker?
Melatonin is not a direct DHT blocker but rather an agent with indirect anti-androgen and strong antioxidant properties. Clinical evidence supports the use of topical melatonin for improving hair density and growth in AGA, particularly in women. Its benefits stem from modulating the hair growth cycle and protecting follicles, not directly inhibiting 5-alpha reductase. Consulting a healthcare professional is vital for determining suitable hair loss treatments. Research, including reviews from the National Institutes of Health, suggests topical melatonin is a well-tolerated option for certain types of hair loss.